This session takes the discussion one step further, discussing actionable strategies for designing trials that are scientifically robust and clinically feasible.

• What are the clinician adaptations needed from standardized imaging to robust progression tracking and integration of real world data
• What will drug developers need to compromise on? Acceptance of subjectivity, broader inclusion, hybrid models combining quantitative metrics and clinical judgement
• What are the pragmatic trial designs: real-world-aligned endpoints, scalable enrichment strategies, and adaptable study protocols